Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Osanetant – Novel Investigational Agent for Treatment of Schizophrenia

Drug (brand/generic)

Osanetant (SR-142801

Company/licensee

Sanofi-Aventis

Therapy class

Antipsychotic

Product description

NK3 receptor antagonist

Current indication

Treatment of schizophrenia

Market sector

CNS

Development status

Discontinued
Expand

Go Top